Fulgent Genetics
Market Cap
US$222.3m
Last Updated
2020/04/09 04:45 UTC
Data Sources
Company Financials +
Executive Summary
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with high growth potential.
Similar Companies
Share Price & News
How has Fulgent Genetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FLGT's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
2.8%
FLGT
11.6%
US Healthcare
9.4%
US Market
1 Year Return
54.5%
FLGT
7.2%
US Healthcare
-6.8%
US Market
Return vs Industry: FLGT exceeded the US Healthcare industry which returned -1.9% over the past year.
Return vs Market: FLGT exceeded the US Market which returned -10% over the past year.
Shareholder returns
| FLGT | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.8% | 11.6% | 9.4% |
| 30 Day | -32.4% | -4.2% | -3.9% |
| 90 Day | -25.7% | -11.5% | -16.5% |
| 1 Year | 54.5%54.5% | 8.6%7.2% | -4.8%-6.8% |
| 3 Year | -5.0%-5.0% | 29.7%23.9% | 23.4%15.2% |
| 5 Year | n/a | 34.8%25.6% | 41.3%25.7% |
Price Volatility Vs. Market
How volatile is Fulgent Genetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
When Will Fulgent Genetics, Inc. (NASDAQ:FLGT) Breakeven?1 month ago | Simply Wall St
A Look At The Fair Value Of Fulgent Genetics, Inc. (NASDAQ:FLGT)1 month ago | Simply Wall St
If You Had Bought Fulgent Genetics (NASDAQ:FLGT) Shares A Year Ago You'd Have Made 281%Valuation
Is Fulgent Genetics undervalued compared to its fair value and its price relative to the market?
2.68x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: FLGT ($9.44) is trading above our estimate of fair value ($3.12)
Significantly Below Fair Value: FLGT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: FLGT is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.
PE vs Market: FLGT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FLGT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FLGT is overvalued based on its PB Ratio (2.4x) compared to the US Healthcare industry average (2.4x).
Next Steps
Future Growth
How is Fulgent Genetics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
147.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FLGT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: FLGT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: FLGT's is expected to become profitable in the next 3 years.
Revenue vs Market: FLGT's revenue (22.2% per year) is forecast to grow faster than the US market (7% per year).
High Growth Revenue: FLGT's revenue (22.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FLGT's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Fulgent Genetics performed over the past 5 years?
22.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FLGT is currently unprofitable.
Growing Profit Margin: FLGT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FLGT is unprofitable, but has reduced losses over the past 5 years at a rate of 22% per year.
Accelerating Growth: Unable to compare FLGT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FLGT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (14%).
Return on Equity
High ROE: FLGT has a negative Return on Equity (-0.5%), as it is currently unprofitable.
Next Steps
Financial Health
How is Fulgent Genetics's financial position?
Financial Position Analysis
Short Term Liabilities: FLGT's short term assets ($37.1M) exceed its short term liabilities ($3.7M).
Long Term Liabilities: FLGT's short term assets ($37.1M) exceed its long term liabilities ($2.3M).
Debt to Equity History and Analysis
Debt Level: FLGT is debt free.
Reducing Debt: FLGT has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable FLGT has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: FLGT is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 24% per year.
Next Steps
Dividend
What is Fulgent Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FLGT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate FLGT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FLGT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FLGT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FLGT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.8yrs
Average management tenure
CEO
Ming Hsieh (63yo)
3.92s
Tenure
US$240,000
Compensation
Mr. Ming Hsieh is the Founder of Fulgent Genetics, Inc. and has been its President & Chief Executive Officer since May 2016 and served as its Manager. Mr. Hsieh serves as President at Fulgent Therapeutics, ...
CEO Compensation Analysis
Compensation vs Market: Ming's total compensation ($USD240.00K) is below average for companies of similar size in the US market ($USD1.51M).
Compensation vs Earnings: Ming's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 3.92yrs | US$240.00k | 36.62% $81.4m | |
| Chief Financial Officer | 4.25yrs | US$241.12k | 1.61% $3.6m | |
| Chief Scientific Officer & Laboratory Director | 3.58yrs | US$216.30k | 5.88% $13.1m | |
| Chief Commercial Officer | 0.083yr | no data | no data |
3.8yrs
Average Tenure
52yo
Average Age
Experienced Management: FLGT's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 3.92yrs | US$240.00k | 36.62% $81.4m | |
| Independent Director | 3.58yrs | US$72.60k | 0.018% $40.2k | |
| Independent Director | 3.58yrs | US$53.50k | 2.44% $5.4m | |
| Independent Director | 3.58yrs | US$70.10k | 0.027% $60.6k | |
| Director | 0.67yr | no data | no data |
3.6yrs
Average Tenure
65yo
Average Age
Experienced Board: FLGT's board of directors are considered experienced (3.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.
Top Shareholders
Company Information
Fulgent Genetics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Fulgent Genetics, Inc.
- Ticker: FLGT
- Exchange: NasdaqGM
- Founded: 2011
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$222.335m
- Shares outstanding: 21.56m
- Website: https://www.fulgentgenetics.com
Number of Employees
Location
- Fulgent Genetics, Inc.
- 4978 Santa Anita Avenue
- Suite 205
- Temple City
- California
- 91780
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| FLGT | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Sep 2016 |
| 7F0 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Sep 2016 |
Biography
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/09 04:45 |
| End of Day Share Price | 2020/04/08 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.